GEN Exclusives

More »

GEN Exclusives

GEN Exclusives provide you with unique, in-depth, and critical coverage of key industry developments, market moving events, and scientific advances, as well as interviews with life science thought leaders. Also included are feature articles from GEN’s print edition.

Insight & Intelligence™: May 18, 2015

Evolution of MicroRNA Research Over the Past Decade

More than 20,000 microRNA-Focused Publications Were Assessed as a Means to Characterize the Field

Evolution of MicroRNA Research Over the Past Decade

Analyses like these help frame the association of miRNAs with specific disease classes and physiological stats. [iStock/© ktsimage]

    The focus of this GEN Market & Tech Analysis report is mapping microRNA research.

    • We have sought to understand the trajectory of microRNA research that has taken place over the past decade
    • We’ve examined the growth of the biological content over this period as well as segmented the entire ensemble of microRNA-focused publications based on disease classes/biologies focused
    • We demonstrate the specific documented associations between “microRNA signatures” and “biological entities” — both in terms of specific content but also time when such association was published
    • These associations and their patterns, primarily in various forms of cancer, but also in other disease classes are important as they illustrate not only the microRNAs per se and their potential value as biomarkers but also which disease classes have “heavy” documented associations and others with “light” associations.

Add a comment

  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Cancer Drug Approvals and Efficacy

Do you think regulatory agencies should be required to provide stronger evidence of the clinical effectiveness of cancer drugs, including a greater emphasis on patient survival time?

More »